Chemed's Revenue in the fiscal year 2025 $ 2,529.98 millions
Chemed's Revenue in the fiscal year 2024 $ 2,431.29 millions
Chemed's Revenue in the fiscal year 2023 $ 2,264.42 millions
Chemed's Revenue in the fiscal year 2022 $ 2,134.96 millions
Chemed's Revenue in the fiscal year 2021 $ 2,139.26 millions
CHE Revenue third quarter 2026 Y/Y Growth Comment
Chemed Corporation achieved in the third quarter 2026, above Company average Revenue increase of 10.57% year on year, to $ 690.94 millions.
Looking into third quarter 2026 results within Healthcare Facilities industry 12 other companies have achieved higher Revenue growth. While Chemed Corporation' s Revenue growth of 10.57% ranks overall at the positon no. 1886 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Chemed's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
8.68 %
1.22 %
-4.57 %
(Dec 31 2019)
CHE's III. Quarter Q/Q Revenue Comment
Chemed Corporation achieved in the III. Quarter 2026 above company average sequential Revenue growth of 2.63%, to $ 690.94 millions, from $673.25 millions in the second quarter. CHE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Healthcare Facilities industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Chemed's Revenue growth quarter on quarter, overall rank is 1445.
Chemed Corporation achieved in the III. Quarter 2026 above company average sequential Revenue growth of 2.63%, to $ 690.94 millions, from $673.25 millions in the second quarter. CHE is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Healthcare Facilities industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Chemed's Revenue growth quarter on quarter, overall rank is 1445.
Chemed saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.15% year on year, to $ 2,661 millions if the fiscal year would have ended in Sep 30 2026. Chemed's trailing twelve months Revenue growth was higher than company's average 4.77% and higher than 3.31% growth in Jun 30 2026. But from twelve months ended Jun 30 2026 rise was beneth at 2.54 % from $2595 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at4.77%.
In the Healthcare sector 279 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 235 to 1768.
Chemed saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 5.15% year on year, to $ 2,661 millions if the fiscal year would have ended in Sep 30 2026. Chemed's trailing twelve months Revenue growth was higher than company's average 4.77% and higher than 3.31% growth in Jun 30 2026. But from twelve months ended Jun 30 2026 rise was beneth at 2.54 % from $2595 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at4.77%. The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 2.54 % increase from $2595 millions in the period from Jun 30 2026 to Sep 30 2025.
In the Healthcare sector 279 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 235 to 1768.
About Chemed Revenue Growth Rates (CHE), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.